NeuroPace (NPCE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NPCE NeuroPace

Watchlist

11.190
-0.740-6.20%

Close Dec 4 16:00 ET

11.190
0.0000.00%

Post 16:00 ET

334.00MMarket Cap-11418P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
GlobeNewswire16:05 ET
NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome; Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its...
BenzingaDec 3 16:16 ET
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
GlobeNewswireDec 3 16:05 ET
Express News | Neuropace Completes Enrollment in Feasibility Study of Rns System for Lennox-Gastaut Syndrome
ReutersDec 3 16:05 ET
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsNov 22 07:31 ET · Ratings
Strong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market Advancements
TipRanksNov 22 06:35 ET

Comments

Moomoo AI

Mar 7 13:13

Analysts show improved sentiment towards NeuroPace, upgrading their numbers and reducing losses per share. A wide gap in price targets implies a broad range of business scenarios. NeuroPace is expected to outpace industry growth.

Earnings Update: Here's Why Analysts Just Lifted Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$16.00

Moomoo AI

Feb 8 14:14

NeuroPace's high P/S ratio is justified by expected strong revenue growth, outpacing the Medical Equipment industry. Shareholders are optimistic about future revenues, holding onto their shares.

NeuroPace, Inc.'s (NASDAQ:NPCE) P/S Is Still On The Mark Following 34% Share Price Bounce

Analysts Notebook

Apr 6, 2022 06:01

Columns Top upgrades and downgrades on 4/6

Upgrades
• $Banc of California (BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers (CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger (GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc (INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp (PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...

Rama Krishna Gonga

Sep 22, 2021 06:11

$NeuroPace (NPCE.US)$ So the price action on this really looks like the bull run will take it up.
It recently ipo'd so theres a ton of volume surging through this.
The macd doesnt look to good but it could continue to churn upward.
The vortex5 its about to cross the .75 line and would that be the buy signal?
Will we see institutional buying at these levels?